Health-related quality of life in patients treated with pembrolizumab for microsatellite instability-high/mismatch repair-deficient advanced solid tumours: Results from the KEYNOTE-158 study. - Université de Lille Accéder directement au contenu
Article Dans Une Revue European Journal of Cancer Année : 2022

Health-related quality of life in patients treated with pembrolizumab for microsatellite instability-high/mismatch repair-deficient advanced solid tumours: Results from the KEYNOTE-158 study.

M. Maio
  • Fonction : Auteur
M. M. Amonkar
  • Fonction : Auteur
J. M. Norquist
  • Fonction : Auteur
P. A. Ascierto
  • Fonction : Auteur
L. Manzyuk
  • Fonction : Auteur
D. Motola-Kuba
  • Fonction : Auteur
Philippe A. Cassier
  • Fonction : Auteur
G. M. Bariani
  • Fonction : Auteur
A. de Jesus Acosta
  • Fonction : Auteur
T. Doi
  • Fonction : Auteur
F. Longo
  • Fonction : Auteur
W. H. Miller
  • Fonction : Auteur
D. Y. Oh
  • Fonction : Auteur
M. Gottfried
  • Fonction : Auteur
R. Wang
  • Fonction : Auteur
K. Norwood
  • Fonction : Auteur

Résumé

Background In the KEYNOTE-158 study (NCT02628067), pembrolizumab showed a high objective response rate and durable clinical benefit for patients with previously treated, unresectable/metastatic microsatellite instability−high (MSI-H)/mismatch repair‒deficient (dMMR) non-colorectal solid tumours. We present health-related quality of life (HRQoL) results from the MSI-H/dMMR population (cohort K). Patients and methods Eligible patients had previously treated MSI-H/dMMR advanced non-colorectal solid tumours, measurable disease per RECIST v1.1, and ECOG performance status ≤1. Patients received pembrolizumab 200 mg Q3W for 35 cycles (2 years). The EORTC Quality of Life Questionnaire (QLQ-C30) and EQ-5D-3L were administered at baseline, at regular intervals throughout treatment, and 30 days after treatment discontinuation. Prespecified analyses (exploratory endpoints) included the magnitude of change from baseline to post-baseline timepoints in all patients and by the best overall response for QLQ-C30 global health status (GHS)/QoL, QLQ-C30 functional/symptom scales/items, and EQ-5D-3L visual analogue scale (VAS) score. Results At data cutoff (October 5, 2020), 351 patients were enrolled, of whom 311 and 315 completed baseline QLQ-C30 and EQ-5D-3L questionnaires, respectively. QLQ-C30 GHS/QoL scores improved from baseline to week 9 (mean [95% CI] change, 3.07 [0.19–5.94]), then remained stable or improved by week 111, with greater improvements observed in patients with a best response of complete response (CR) or partial response (PR) (10.85 [6.36–15.35]). Patients with CR/PR showed improvements in physical (5.58 [1.91–9.25]), role (9.88 [3.80–15.97]), emotional (5.62 [1.56–9.68]), and social (8.33 [2.70–13.97]) functioning, and stable cognitive functioning (1.74 [−1.45 to 4.94]). Conclusions Pembrolizumab generally improved or preserved HRQoL in patients with previously treated MSI-H/dMMR advanced non-colorectal solid tumours.
Fichier principal
Vignette du fichier
PIIS0959804922001885.pdf (484.08 Ko) Télécharger le fichier
Origine Publication financée par une institution
Licence

Dates et versions

hal-04573604 , version 1 (22-05-2024)

Licence

Identifiants

Citer

M. Maio, M. M. Amonkar, J. M. Norquist, P. A. Ascierto, L. Manzyuk, et al.. Health-related quality of life in patients treated with pembrolizumab for microsatellite instability-high/mismatch repair-deficient advanced solid tumours: Results from the KEYNOTE-158 study.. European Journal of Cancer, 2022, European Journal of Cancer, 169, pp.188-197. ⟨10.1016/j.ejca.2022.03.040⟩. ⟨hal-04573604⟩
8 Consultations
1 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More